This report describes the evidence and policy needs of global and country decision-makers, public health program planners, and implementers that may be involved in maternal respiratory syncytial virus (RSV) vaccine decisions or delivery. The report focuses specifically on the context of potential introduction in low- and middle-income countries (LMICs) and summarizes relevant evidence across the following broad topic areas: 1) disease, 2) product, 3) health economics and financing, and 4) vaccine service delivery. Critical gaps in evidence are highlighted that, if left unfilled, could delay or preclude vaccine introduction in LMICs.

Advancing Maternal Immunization (AMI) is a collaboration of cross-sectoral experts convened by PATH and WHO with the purpose of advancing RSV MI.